Literature DB >> 9705567

Magnesium deficiency induces bone loss in the rat.

R K Rude1, M E Kirchen, H E Gruber, A A Stasky, M H Meyer.   

Abstract

Disorders in which magnesium (Mg) depletion is common have an associated high incidence of osteoporosis. Mg depletion in humans results in hypocalcemia, low serum parathyroid hormone (PTH) and 1, 25(OH)2-vitamin D levels, as well as PTH and vitamin D resistance which may serve as mechanisms for the development of osteoporosis. In order to determine if isolated Mg depletion will result in bone loss, we have induced dietary Mg deficiency in the rat. Adult (290 g) female rats were given either a low-Mg diet (2 mg/100 g chow; n = 6) or a normal control Mg diet (63 mg/100 g chow; n = 6). Dietary calcium (Ca) was normal in both groups (592 mg/100 g chow). At 12 weeks, blood was obtained for serum Mg, Ca, PTH, 1,25(OH)2-vitamin D, and osteocalcin determinations. The rats were then euthanized and the femurs obtained for mineral analysis and histomorphometry. Serum Mg in the low-Mg group was less than control (0.4 +/- 0.2 vs. 1.9 +/- 0.2 mg/dl, p < 0.001; mean +/- SD) while serum Ca was higher (11. 7 +/- 0.5 vs. 9.3 +/- 0.4 mg/dl, p < 0.001). PTH was suppressed in the Mg-deficient group (36 +/- 16 vs. 109 +/- 30 pg/ml in controls, p < 0.002). Serum 1,25(OH)2-vitamin D was also suppressed in the Mg-deficient animals (7.1 +/- 4.8 vs. 28.5 +/- 8.2 pg/ml in controls, p < 0.002). Serum osteocalcin levels were not different (19.8 +/- 2.5 ng/ml in Mg-deficient rats vs. 15.3 +/- 3.4 ng/ml in controls). While the ash weight of Ca and phosphorus in the femur did not change, the ash weight of Mg fell (low-Mg group 0.55 +/- 0.01%, controls 0.65 +/- 0.02%, p < 0.001). Histomorphometry demonstrated reduction in bone mass; the trabecular bone volume in the femur of the low-Mg group was reduced from control (7.7 +/- 0.2 vs. 13.7 +/- 1.9%, p < 0.002). A surprising new observation was an increase in osteoclast (OC) bone resorption with Mg depletion. The number of OC per millimeter bone surface was 16.9 +/- 1.3 in the low-Mg group versus 7.8 +/- 1.5 in controls (p < 0.001). The percentage of bone surface occupied by OC was 38.3 +/- 3.7 in the low-Mg group versus 17.7 +/- 2.4 in controls (p < 0.001). This increased resorption occurred with an inappropriate non-altered bone-forming surface relative to control (% osteoid surface: low-Mg group 2.4 +/- 0.7 vs. controls 2.6 +/- 0.4; % osteoid volume: low-Mg group 0.25 +/- 0.09 vs. controls 0.38 +/- 0.06; number of osteoblasts per millimeter bone surface: low-Mg group 0.9 +/- 0.3 vs controls 1.3 +/- 0.3). No increase in bone-forming surface or osteoblast number despite an increase in OC-resorbing surface and OC number strongly suggests impaired activation of osteoblasts and an uncoupling of bone formation and bone resorption. Our data demonstrate that Mg depletion in the rat alters bone and mineral metabolism which results in bone loss.

Entities:  

Mesh:

Year:  1998        PMID: 9705567     DOI: 10.1159/000057389

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  4 in total

1.  Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum.

Authors:  Qiaoli Li; Jennifer Larusso; Alix E Grand-Pierre; Jouni Uitto
Journal:  Clin Transl Sci       Date:  2009-12       Impact factor: 4.689

2.  Infrared analysis of bones in magnesium-deficient rats treated with vitamin K2.

Authors:  Masatoshi Kobayashi; Kuniko Hara; Yasuhiro Akiyama
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

3.  Reduction of dietary magnesium by only 50% in the rat disrupts bone and mineral metabolism.

Authors:  R K Rude; H E Gruber; H J Norton; L Y Wei; A Frausto; J Kilburn
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

Review 4.  'Magnesium'-the master cation-as a drug-possibilities and evidences.

Authors:  Aparna Ann Mathew; Rajitha Panonnummal
Journal:  Biometals       Date:  2021-07-02       Impact factor: 2.949

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.